Search Bar & Filters
Found 2 Actively Recruiting clinical trials
Actively Recruiting
Researchers are evaluating the antiviral effects of S-337395 compared to a placebo in adults who are not hospitalized but have respiratory syncytial virus RSV infection and are at high risk of progressing to severe disease. This phase 2b study focuses on participants starting treatment within 72 hours of RSV symptom onset to assess safety, tolerability, and efficacy. The trial includes adults with specific risk factors such as advanced age and chronic lung or cardiovascular diseases. Participants are randomly assigned to one of three groups a high dose of S-337395 taken orally twice daily for up to 5 days, a low dose of S-337395 taken with the same schedule, or a matching placebo given twice daily for 5 days. The study uses a double-blind design to compare the effects of these treatments. During the study, participants will undergo nasal swabs to measure changes in RSV viral load at multiple time points days 2, 4, and 6. Researchers will also monitor RSV symptom severity, time to symptom resolution, and the presence of the virus over the first 6 days. Safety is assessed by recording any treatment-emergent adverse events up to 28 days after starting treatment. Blood samples will measure the concentration of S-337395, and participants will be observed throughout the treatment and follow-up periods.
Actively Recruiting
This research aims to collect real-world data on patients with type 2 diabetes, hypertension, heart failure, and chronic kidney disease. It focuses on understanding patient characteristics, disease management, healthcare use, and outcomes across many countries. The study is an observational registry that includes patients seen in regular clinical practice worldwide. Participants are grouped based on their main condition or comorbidities, including type 2 diabetes, hypertension, chronic kidney disease, or heart failure. Data is collected both retrospectively and prospectively using a cloud-based electronic case report form accessible to investigators and a scientific committee. The registry is open to all physicians managing these conditions globally. Participants contribute information about their health status, treatments, and clinical measurements over time. Researchers gather demographic data, disease history, lab tests, imaging, medication use, healthcare visits, and outcomes such as hospitalizations and complications. The study measures many health indicators at baseline and averages over three years to understand care quality and disease progression. Participation can last until the study ends in 2030.